124 research outputs found
Scholion, in omnes Novi Testamenti libros : quo loci difficiles, aut etiam ambigui, iuxta originalem Scripturae phrasim, ac vetustissimarum theologorum citationum... /
BHR/A-039-298 (1)(BIB LVL) w-FONDO ANTIGUO(ES-GrU)b11007229-34cbua_ugrZeger, Tacitus NicolausScholion, in omnes Novi Testamenti libros :Coloniae Agrippinae :[8], 168 [i.e. 170] h.Marca tip. en port.Error de pag., de h. 167 pasa a 166Esta digitalización se ha realizado con fondos del Ministerio de Cultura y Deport
an ALWP-EBMT study
Background Allogeneic stem cell transplantation is the only curative option
for patients with acute myeloid leukemia (AML) experiencing relapse. Either
matched sibling donor (MSD) or unrelated donor (UD) is indicated. Methods We
analyzed 1554 adults with AML transplanted from MSD (n = 961) or UD (n = 593,
HLA-matched 10/10, n = 481; 9/10, n = 112). Compared to MSD, UD recipients
were older (49 vs 52 years, p = 0.001), transplanted more recently (2009 vs
2006, p = 0.001), and with a longer interval to transplant (10 vs 9 months, p
= 0.001). Conditioning regimen was more frequently myeloablative for patients
transplanted with a MSD (61 vs 46 %, p = 0.001). Median follow-up was 28
(range 3–157) months. Results Cumulative incidence (CI) of neutrophil
engraftment (p = 0.07), grades II–IV acute GVHD (p = 0.11), chronic GVHD (p =
0.9), and non-relapse mortality (NRM, p = 0.24) was not different according to
the type of donor. At 2 years, CI of relapse (relapse incidence (RI)) was 57
vs 49 % (p = 0.001). Leukemia-free survival (LFS) at 2 years was 21 vs 26 % (p
= 0.001), and overall survival (OS) was 26 vs 33 % (p = 0.004) for MSD vs UD,
respectively. Chronic GVHD as time-dependent variable was associated with
lower RI (HR 0.78, p = 0.05), higher NRM (HR 1.71, p = 0.001), and higher OS
(HR 0.69, p = 0.001). According to HLA match, RI was 57 vs 50 vs 45 %, (p =
0.001) NRM was 23 vs 23 vs 29 % (p = 0.26), and LFS at 2 years was 21 vs 27 vs
25 % (p = 0.003) for MSD, 10/10, and 9/10 UD, respectively. In multivariate
analysis adjusted for differences between the two groups, UD was associated
with lower RI (HR 0.76, p = 0.001) and higher LFS (HR 0.83, p = 0.001)
compared to MSD. Interval between diagnosis and transplant was the other
factor associated with better outcomes (RI (HR 0.62, p < 0.001) and LFS (HR
0.67, p < 0.001)). Conclusions Transplantation using UD was associated with
better LFS and lower RI compared to MSD for high-risk patients with AML
transplanted in first relapse
The Correlation of the NA Measurements by Counting 28Si Atoms
open12sìpartially_openembargoed_20160715Mana, G.; Massa, E.; Sasso, C. P.; Stock, M.; Fujii, K.; Kuramoto, N.; Mizushima, S.; Narukawa, T.; Borys, M.; Busch, I.; Nicolaus, A.; Pramann, A.Mana, Giovanni; Massa, Enrico; Sasso, CARLO PAOLO; Stock, M.; Fujii, K.; Kuramoto, N.; Mizushima, S.; Narukawa, T.; Borys, M.; Busch, I.; Nicolaus, A.; Pramann, A
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors : a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
Allogeneic hematopoietic cell transplantation (allo-HCT) remains a treatment option for patients with chronic myeloid leukemia (CML) who fail to respond to tyrosine kinase inhibitors (TKIs). While imatinib seems to have no adverse impact on outcomes after transplant, little is known on the effects of prior use of second-generation TKI (2GTKI). We present the results of a prospective non-interventional study performed by the EBMT on 383 consecutive CML patients previously treated with dasatinib or nilotinib undergoing allo-HCT from 2009 to 2013. The median age was 45 years (18-68). Disease status at transplant was CP1 in 139 patients (38%), AP or >CP1 in 163 (45%), and BC in 59 (16%). The choice of 2GTKI was: 40% dasatinib, 17% nilotinib, and 43% a sequential treatment of dasatinib and nilotinib with or without bosutinib/ponatinib. With a median follow-up of 37 months (1-77), 8% of patients developed either primary or secondary graft failure, 34% acute and 60% chronic GvHD. There were no differences in post-transplant complications between the three different 2GTKI subgroups. Non-relapse mortality was 18% and 24% at 12 months and at 5 years, respectively. Relapse incidence was 36%, overall survival 56% and relapse-free survival 40% at 5 years. No differences in post-transplant outcomes were found between the three different 2GTKI subgroups. This prospective study demonstrates the feasibility of allo-HCT in patients previously treated with 2GTKI with a post-transplant complications rate comparable to that of TKI-naive or imatinib-treated patients.Peer reviewe
- …